| Previous Close | 50.80 |
| Open | 50.98 |
| Bid | 50.80 x 200 |
| Ask | 50.81 x 2400 |
| Day's Range | 50.62 - 51.00 |
| 52 Week Range | 37.38 - 51.13 |
| Volume | 2,403,279 |
| Avg. Volume | 6,392,669 |
| Market Cap | 88.07B |
| Beta | 1.54 |
| PE Ratio (TTM) | 52.81 |
| EPS (TTM) | 0.96 |
| Earnings Date | Oct 17, 2017 - Oct 23, 2017 |
| Dividend & Yield | 1.06 (2.08%) |
| Ex-Dividend Date | 2017-07-12 |
| 1y Target Est | 55.06 |
- Market Realist•18 minutes ago
Abbott Laboratories’ 2Q17 Results: Which Segment Fared Best?
In 2Q17, Abbott Laboratories' (ABT) Medical Devices segment reported a strong performance once again, registering a YoY sales growth of 89.2%.
- Market Realist•2 hours ago
Strong 2Q17 Results Trigger Rise in Abbott Stock
On July 20, 2017, Abbott Laboratories (ABT) released its 2Q17 earnings. That day, ABT stock rose more than 4.0% from its closing price of $49.40 on July 19, 2017.
- American City Business Journals•21 hours ago
Abbott deal will cost Alere three business units — and untold employees
When it completes its $5.3 billion acquisition of Waltham-based Alere later this year, Abbott Laboratories will be getting one of the world’s largest makers of point-of-care diagnostic tests, a fast-growing sector. Thanks to antitrust rules, though, Abbott (ABT) will be taking on a slimmed-down version of Alere (ALR) by the end of September. Back in January, Illinois-based Abbott agreed to divest three Alere business units that make competing products in order to secure the approval of European Union antitrust regulators.
